Department of Radiology, Yokohama City University Hospital, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Ann Nucl Med. 2010 May;24(4):241-7. doi: 10.1007/s12149-010-0363-0. Epub 2010 Mar 24.
The aim of our study was to evaluate detectability of bone metastatic lesions and evaluate the correlation between (18)F-fluoride uptake patterns on positron emission tomography (PET) and morphologic changes on CT using integrated PET/CT.
We performed whole-body (18)F-fluoride PET/CT staging for 27 patients with known cancer. Tumor types comprised breast (n = 7), prostate (n = 7), and others (n = 13). A total of 154 uptake lesions were evaluated. Both tracer uptake patterns determined by (18)F-fluoride PET and morphologic patterns based on CT findings such as morphologic changes, involved locations, and grades scored using five-point scale were compared with histologic tumor subtypes and clinical laboratory data.
CT patterns of metastatic lesion were lytic or unclassified in 26 lesions, sclerotic in 53 lesions, and mixed in 75 lesions. Multiple linear regression analysis revealed that metastatic bone lesions with high maximum standardized uptake value (SUVmax) tended to show sclerotic or mixed changes on CT (P < 0.0001), and were also distributed in bone cortex alone or both bone cortex and medulla (P < 0.0001).
In patients with bone metastasis, the lesions with sclerotic or mixed changes or located in bone cortex alone or both bone cortex and medulla tend to show high SUVmax on (18)F-fluoride PET/CT.
我们研究的目的是评估骨转移病灶的可探测性，并评估正电子发射断层扫描（PET）中（18）F-氟化物摄取模式与集成 PET/CT 上 CT 形态变化之间的相关性。
我们对 27 例已知癌症患者进行了全身（18）F-氟化物 PET/CT 分期。肿瘤类型包括乳腺癌（n=7）、前列腺癌（n=7）和其他肿瘤（n=13）。共评估了 154 个摄取病灶。（18）F-氟化物 PET 确定的示踪剂摄取模式以及 CT 发现的形态学变化、受累部位以及使用五分制评分的等级等形态学模式与组织学肿瘤亚型和临床实验室数据进行了比较。
26 个转移病灶的 CT 表现为溶骨性或未分类，53 个为硬化性，75 个为混合性。多元线性回归分析显示，最大标准化摄取值（SUVmax）较高的转移性骨病灶在 CT 上更倾向于表现为硬化性或混合性改变（P<0.0001），并且还分布在骨皮质或骨皮质和骨髓中（P<0.0001）。
在骨转移患者中，表现为硬化性或混合性改变或位于骨皮质或骨皮质和骨髓中的病灶在（18）F-氟化物 PET/CT 上更倾向于显示高 SUVmax。
